This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Globus Medical Global Base Solid, Pricing Scenario Bothers
by Zacks Equity Research
Globus Medical (GMED) is upbeat about its growth prospects in the current and the emerging global markets through a continual expansion of direct and distributor sales forces.
Globus Medical (GMED) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 7.50% and 0.22%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Surges: Stock Moves 7.1% Higher
by Zacks Equity Research
Globus Medical (GMED) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
New Strong Buy Stocks for December 20th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Globus Medical (GMED) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 18.18% and 1.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ITGR vs. GMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. GMED: Which Stock Is the Better Value Option?
ITGR vs. GMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ITGR vs. GMED: Which Stock Is the Better Value Option?
Opko Health (OPK) in Focus: Stock Moves 6% Higher
by Zacks Equity Research
Shares of Opko Health (OPK) rose nearly 6% on Friday.
Globus Medical (GMED) Looks Good: Stock Adds 7.5% in Session
by Zacks Equity Research
Globus Medical (GMED) saw its shares rise nearly 8% on the day after the company reported year-over-year growth in third-quarter earnings and revenues.
Globus Medical (GMED) Q3 Earnings In Line, View Reiterated
by Zacks Equity Research
Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.
Globus Medical's Robotic Guidance System Gets FDA Approval
by Zacks Equity Research
Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.
Globus Medical (GMED) Stock is Popping: Here's Why
by Madeleine Johnson
On Thursday, shares of medical device company Globus Medical Inc. (GMED) are popping, up almost 6% in late-morning trading after the firm announced that the FDA granted 510(k) clearance to one of its key products, the robotic guidance and navigation system Excelsius GPS.